









Markets
/
Stocks
/
nasdaq-otlk
/

Outlook Therapeutics Inc

OTLK

0.963USD

-0.027-2.73%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

41.87MMarket Cap

LossP/E TTM



Outlook Therapeutics Inc

0.963

-0.027-2.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

177 / 506

Overall Ranking

297 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Hold

Current Rating

8.333

Target Price

+716.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Fairly Valued

The company’s latest PE is -1.17, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 23.11M shares, increasing 8.54% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.25M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.63.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.76, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.76

Change



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.82

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.20, which is -23.33% below the recent high of -0.92 and -162.27% above the recent low of -3.16.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 177/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 6.80, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Outlook Therapeutics Inc is 8.00, with a high of 21.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Hold

Current Rating

8.333

Target Price

+741.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Outlook Therapeutics Inc

OTLK

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.10, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 2.68 and the support level at 0.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.10

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.010

Neutral

RSI(14)

34.892

Neutral

STOCH(KDJ)(9,3,3)

32.502

Sell

ATR(14)

0.101

Low Volatility

CCI(14)

-3.273

Neutral

Williams %R

61.252

Sell

TRIX(12,20)

-3.073

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.021

Sell

MA10

1.011

Sell

MA20

1.318

Sell

MA50

1.817

Sell

MA100

1.768

Sell

MA200

1.707

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 54.78%, representing a quarter-over-quarter increase of 5.78%. The largest institutional shareholder is The Vanguard, holding a total of 1.25M shares, representing 2.82% of shares outstanding, with 21.82% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

GMS Ventures and Investments

13.55M

+46.25%

Syntone Ventures LLC

1.71M

+72.07%

Schonfeld Strategic Advisors LLC

1.55M

The Vanguard Group, Inc.

Star Investors

837.41K

-1.78%

Tenshi Healthcare Pte. Ltd

831.85K

-14.03%

Steward Partners Investment Advisory, LLC

366.20K

+2615621.43%

BlackRock Institutional Trust Company, N.A.

1.18M

+14.52%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.55. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.